Literature DB >> 18930043

Brain regions mediating alpha3beta4 nicotinic antagonist effects of 18-MC on methamphetamine and sucrose self-administration.

Stanley D Glick1, Elizabeth M Sell, Isabelle M Maisonneuve.   

Abstract

The novel iboga alkaloid congener 18-methoxycoronaridine (18-MC) is a putative anti-addictive agent that has been shown, in rats, to decrease the self-administration of several drugs of abuse. Previous work has established that 18-MC is a potent antagonist at alpha3beta4 nicotinic receptors. Because high densities of alpha3beta4 nicotinic receptors occur in the medial habenula and the interpeduncular nucleus and moderate densities occur in the dorsolateral tegmentum, ventral tegmental area, and basolateral amygdala, the present study was conducted to determine if 18-MC could act in these brain areas to modulate methamphetamine self-administration in rats. Local administration of 18-MC into either the medial habenula, the interpeduncular area or the basolateral amygdala decreased methamphetamine self-administration. Similar results were produced by local administration into the same brain areas of two other alpha3beta4 nicotinic antagonists, mecamylamine and alpha-conotoxin AuIB. Local administration of 18-MC, or the other antagonists, into the dorsolateral tegmentum or the ventral tegmental area had no effect on methamphetamine self-administration. In contrast, local administration of 18-MC and the other antagonists decreased sucrose self-administration when administered into the dorsolateral tegmentum or basolateral amygdala but had no effect when infused into the medial habenula, interpeduncular nucleus, or ventral tegmental area. These data are consistent with the hypothesis that 18-MC decreases methamphetamine self-administration by indirectly modulating the dopaminergic mesolimbic pathway via blockade of alpha3beta4 nicotinic receptors in the habenulo-interpeduncular pathway and the basolateral amygdala. The data also suggest that the basolateral amygdala along with a different pathway involving alpha3beta4 receptors in the dorsolateral tegmentum mediate the effect of 18-MC on sucrose self-administration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18930043      PMCID: PMC2600595          DOI: 10.1016/j.ejphar.2008.09.038

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  47 in total

1.  Lateral habenula as a source of negative reward signals in dopamine neurons.

Authors:  Masayuki Matsumoto; Okihide Hikosaka
Journal:  Nature       Date:  2007-05-23       Impact factor: 49.962

2.  The potential anti-addictive agent, 18-methoxycoronaridine, blocks the sensitized locomotor and dopamine responses produced by repeated morphine treatment.

Authors:  K K Szumlinski; I M Maisonneuve; S D Glick
Journal:  Brain Res       Date:  2000-05-02       Impact factor: 3.252

3.  Interactions between iboga agents and methamphetamine sensitization: studies of locomotion and stereotypy in rats.

Authors:  K K Szumlinski; M Y Balogun; I M Maisonneuve; S D Glick
Journal:  Psychopharmacology (Berl)       Date:  2000-08       Impact factor: 4.530

4.  Interactions between 18-methoxycoronaridine (18-MC) and cocaine: dissociation of behavioural and neurochemical sensitization.

Authors:  K K Szumlinski; C A McCafferty; I M Maisonneuve; S D Glick
Journal:  Brain Res       Date:  2000-07-21       Impact factor: 3.252

5.  18-MC reduces methamphetamine and nicotine self-administration in rats.

Authors:  S D Glick; I M Maisonneuve; H A Dickinson
Journal:  Neuroreport       Date:  2000-06-26       Impact factor: 1.837

6.  Nicotine modulates evoked GABAergic transmission in the brain.

Authors:  P J Zhu; V A Chiappinelli
Journal:  J Neurophysiol       Date:  1999-12       Impact factor: 2.714

7.  Self-stimulation of the habenular complex in the rat.

Authors:  R J Sutherland; S Nakajima
Journal:  J Comp Physiol Psychol       Date:  1981-10

8.  Stimulation of the lateral habenula inhibits dopamine-containing neurons in the substantia nigra and ventral tegmental area of the rat.

Authors:  G R Christoph; R J Leonzio; K S Wilcox
Journal:  J Neurosci       Date:  1986-03       Impact factor: 6.167

9.  The effects of excitotoxic lesions of the basolateral amygdala on the acquisition of heroin-seeking behaviour in rats.

Authors:  H L Alderson; T W Robbins; B J Everitt
Journal:  Psychopharmacology (Berl)       Date:  2000-12       Impact factor: 4.530

10.  Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei.

Authors:  R Klink; A de Kerchove d'Exaerde ; M Zoli; J P Changeux
Journal:  J Neurosci       Date:  2001-03-01       Impact factor: 6.167

View more
  16 in total

1.  AT-1001: a high affinity and selective α3β4 nicotinic acetylcholine receptor antagonist blocks nicotine self-administration in rats.

Authors:  Lawrence Toll; Nurulain T Zaveri; Willma E Polgar; Faming Jiang; Taline V Khroyan; Wei Zhou; Xinmin Simon Xie; Gregory B Stauber; Matthew R Costello; Frances M Leslie
Journal:  Neuropsychopharmacology       Date:  2012-01-25       Impact factor: 7.853

2.  Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration.

Authors:  Sebastien Carnicella; Dao-Yao He; Quinn V Yowell; Stanley D Glick; Dorit Ron
Journal:  Addict Biol       Date:  2010-10       Impact factor: 4.280

3.  Impact of human D398N single nucleotide polymorphism on intracellular calcium response mediated by α3β4α5 nicotinic acetylcholine receptors.

Authors:  Anne Tammimäki; Penelope Herder; Ping Li; Caroline Esch; James R Laughlin; Gustav Akk; Jerry A Stitzel
Journal:  Neuropharmacology       Date:  2012-07-20       Impact factor: 5.250

4.  Interaction of ibogaine with human alpha3beta4-nicotinic acetylcholine receptors in different conformational states.

Authors:  Hugo R Arias; Avraham Rosenberg; Katarzyna M Targowska-Duda; Dominik Feuerbach; Xiao Juan Yuan; Krzysztof Jozwiak; Ruin Moaddel; Irving W Wainer
Journal:  Int J Biochem Cell Biol       Date:  2010-09       Impact factor: 5.085

5.  Brain regions mediating α3β4 nicotinic antagonist effects of 18-MC on nicotine self-administration.

Authors:  Stanley D Glick; Elizabeth M Sell; Sarah E McCallum; Isabelle M Maisonneuve
Journal:  Eur J Pharmacol       Date:  2011-08-19       Impact factor: 4.432

6.  Varenicline and GZ-793A differentially decrease methamphetamine self-administration under a multiple schedule of reinforcement in rats.

Authors:  Megan M Kangiser; Linda P Dwoskin; Guangrong Zheng; Peter A Crooks; Dustin J Stairs
Journal:  Behav Pharmacol       Date:  2018-02       Impact factor: 2.293

7.  18-Methoxycoronaridine blocks acquisition but enhances reinstatement of a cocaine place preference.

Authors:  Sarah E McCallum; Stanley D Glick
Journal:  Neurosci Lett       Date:  2009-04-11       Impact factor: 3.046

8.  Sex differences in tolerance to the locomotor depressant effects of lobeline in periadolescent rats.

Authors:  Steven B Harrod; M Lee Van Horn
Journal:  Pharmacol Biochem Behav       Date:  2009-09-17       Impact factor: 3.533

Review 9.  Potential therapeutic uses of mecamylamine and its stereoisomers.

Authors:  Justin R Nickell; Vladimir P Grinevich; Kiran B Siripurapu; Andrew M Smith; Linda P Dwoskin
Journal:  Pharmacol Biochem Behav       Date:  2013-04-18       Impact factor: 3.533

10.  Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use.

Authors:  Keith G Heinzerling; Aimee-Noelle Swanson; Timothy M Hall; Yi Yi; Yingnian Wu; Steven J Shoptaw
Journal:  Addiction       Date:  2014-08-05       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.